Confirmed Chinese Speakers
Mr. Zhang Qin, was appointed Member of Party Group of China Association for Science and Technology in June 2009 after serving as Deputy Commissioner of the State Intellectual Property Office of the People’s Republic of China (SIPO) from 2003.He was born in March 1956. From March 1978 to October 1987, Mr. Zhang Qin studied at Tsinghua University and obtained Bachelor, Master and Doctor Degrees in Engineering in nuclear reactor technology. From October 1987 to October 1989, Mr. Zhang has been a visiting scholar in University of Tennessee and UCLA. From 1989 to 1991, Mr. Zhang has engaged in post-doctoral study of System Engineering in School of Economics Management, Tsinghua University. He is currently holds professorship in Department of Computer Science, Beijing University of Aeronautics & Astronautics and Mentor of, Automation Institute, Chongqing University where he also supervises PhD Candidates.
Mr. Gao serves as Deputy Director General, Economic Crimes Investigation Bureau, Ministry of Public Security (MPS). He obtained his law degree from Huadong Politics & Law Institute in 1983. Tasked to head investigation of economic crimes, in particular IPR crimes for years, Mr. Gao engineered the policy framework, strategy and rules of IPR criminal protection in China. Orchestrating multiple nationwide police operations combating IPR crimes, he has been heavily exposed to high-profile IPR criminal cases and cross-border enforcement collaboration.
As a renowned IP expert, he spoke at dozens of international and national seminars/training courses, many of which targeting law enforcement officers in foreign countries. Mr. Gao is a keen follower of the emerging issues in law, economics and IPR, editing or co-editing books such as Courses on Commanding Economic Crimes Investigation, Understanding and Application of Laws in Handling Economic Crimes by Police. Since 2003, Mr. Gao designed and organized IPR Criminal Protection in China Forum six years in a row, which has made tremendous impact in the field. In 2008, Mr. Gao was selected as one of the 50 most influential people in the business by the British magazine Managing IP.
Mr. Yin graduated in 1977 from Chongqing University with the major of Industry Automation Instrument, and graduated in 1981 from the Postgraduate School of University of Science and Technology of China,finishing his dissertation in the Automation Research Institute of Chinese Academy of Science (CAS) and obtaining Master of Science degree.
He was also trained in the US Patent and Trademark Office for six months, in Germany Federal Patent Office and Germany Federal Patent Court for six months, in John Mashall Law College (Chicago) for three months, and carried out research work in the Intellectual Property Research Institute of Max Planck Institute of Germany for six months.
Beginning his career with the State Intellectual Property Office (SIPO) since 1982, he consecutively assumed leadership positions as Senior Member of the Patent Appeal Board and Director of Physical Appeal Chamber, Deputy Director General of the Administrative Department of Patent examination, and Director General of the Legal Affairs Department.
Mr. Yin also holds several advisory positions: Councilor of China Law Society, Standing Councilor of Intellectual Property Research Associationof China, Deputy Secretary General of China Brunch of AIPPI, Pluralistic Professor of Huazhong University of Science and Technology, Pluralistic Professor of South-West University of Politics and Law, Honored Professor of Economy Law College of China University of Politics and Law, Honored Professor of Intellectual Property Training Center of SIPO, Senior Researcher of SIPO, Deputy Chairman of SIPO Academic Committee, Consultation Adviser of Beijing Municipality High Court, IPAdviser of Shanghai Municipality High Court, IP Adviser of Jiangsu Province High Court,Consultation Adviser of Fujian Province High Court, and Member of the 16th plenary of Committee of China International Economic and Trade Arbitration Commission. He was appointed as SIPO Speaker in 2007.
He led the preparation on behalf of SIPO the draft for the second revision on the Chinese Patent Laws and its Implementation Regulations and took part in the full course of the revision in the State Council and National People’s Congress. He also headed the Chinese delegations in various meetings of the Standing Committee of Patent (SCP) of WIPO on the Substantive Patent Law Treaty (SPLT) and the meetings on the reform of Patent Cooperation Treaty (PCT), and has acted the Deputy Chairman of the meeting for many times. He was also in charge of SIPO’s role in the third revision of the Chinese Patent Law.
His major publications include: published the Protection for Patent in 1998; published the Detailed Interpretation of New Patent Law in 2001, compiled Guidance on Secondary Modification of Patent Law and the Guidance on Secondary Modification of Implementation Rules of Patent Law in 2001; published the Introduction to Patent Agency in 2002; translated and edited Integration of Intellectual Property and Development Strategy (report of British Intellectual Property Committee) in 2003; published the Protection for Patent (Second Edition) in 2005, totally amount for about 2.5 million Chinese words; released dozens of essays and articles on various domestic as well as foreign intellectual property journals.
Dr. Zhang graduated from Department of Pharmacy, Health Science Center, Peking University and got Bachelor of Science in 1982, and then got Executive Master of Business Administration (EMBA) from China Europe International Business School in 2006.
He worked in Beijing Institute for Drug Control since 1982 and was appointed as director of this institute since 1999. In 2002 he was also appointed to be Deputy Director of Beijing Drug Administration. Since Feb. 2006 he was appointed as Director-General of Department of Drug Registration, State Food and Drug Administration.
Dr. Zhang is Member of the eighth and ninth Chinese Pharmacopeia Commission, Vice-chairman of the Professional Committee of Pharmaceutical Administration of Chinese Pharmaceutical Association, Standing Member of Chinese Research Association of Hospitalization Insurance, and so on.
Mr. Liao obtained his Bachelor’s degree of Engineering in automation control from the University of Science and Technology of China (USTC) in 1986. In 1989, he finished his graduate study in control theory and its application from the Automation Research Institute of Chinese Academy of Sciences (CAS) with a Master’s degree in Engineering. In 2002, Mr. Liao graduated from John Marshall Law School in Chicago, Illinois of the USA with an LLM degree.
Mr. Liao joined Chinese Patent Office in 1989 and later served in the Patent Reexamination Board (PRB) in 1993, where he has successively held the posts of the examiner, the Deputy Division Director, the Division Director, and the Deputy Director General. In 2005, he was appointed to head the PRB to manage the daily affairs.
Mr. Liao sits on the boards of the China Intellectual Property Society (CIPS) and its patent committee, the AIPPI China and the Patent Protection Association of China. He is the member of the editorial boards of the China Invention and Patent magazine and the Academic Counselor of the China Patent Agents magazine. Mr. Liao is also the head of the Reexamination and Invalidation Sub-Committee of the SIPO Academic Committee.
Mr. Zhang is a Master graduated from the Chemical Engineering Department of the Tsinghua University 1981. He works in the Pharmaceutical and Biological Examination Department of the Chinese State Intellectual Property Office as the Director General. His technical Tittle is Professor. He is also a Specialist of the state level.
During the period in the Chinese Patent Office or the Chinese State Intellectual Property Office, Mr. Zhang has visited the German Patent Office, the Max-Planck-Institute, the USPTO, the European Patent Office, the Japan Patent Office, the U.K. Patent Office, the Brazilian Patent Office, the Korean Patent Office and the Spain Patent Office many times. He has published about 100 papers in journals such as GRUR, Chinese Patent and Trademark，Chinese Intellectual Property Newspaper etc., he has also published four books about the Writing and Examination of the Patent Applications, Intellectual Property strategy especially in the Chemical and Pharmaceutical fields.
Mr. Zhang is also a member of the State Leading Group for Research and Development of New Drugs, a member of the Committee of Experts for Research and Development of new Drugs, a member of the State Examining Committee for Protection of the new Chinese Traditional Medicine, a member of the Committee of Experts for Administration Protection of Pharmaceuticals，Chief of the pharmaceutical Intellectual Property Research Committee of Chinese Pharmaceutical Society, a standing member of the board of directors of the Chinese Intellectual Property Society and a Professor of the Chinese Intellectual Property Training Center.
Mr. Zeng studied in Wuhan University from September 1986 to July 1989 and obtained the degree as Master of Science. He studied civil law in The China University of Political Science and Law from September 2001 to February 2003. Mr. Zeng also studied in the John Marshall Law School (USA) and obtained an LLM degree.
He has been working with the in Chemistry Examination Department of SIPO from August 1989and has been the director of pharmaceutical chemistry division, organic chemistry division and natural pharmaceutical chemistry division. He currently assumes the position of Deputy Director General of the department.
Mr. Zhu, the Deputy Director of Patent Examination Cooperation Center of SIPO (State Intellectual Property Office of P.R.China), majored in engineering thermophysics in Department of Power Engineering of Nanjing Institute of Technology (Presently known as School of Energy ＆ Environment of Southeast University) from 1980 to 1984. Later he was employed in the Physics Invention Examination Department of Patent Office of SIPO. In 1992 Mr. Zhu Mingang was appointed as Deputy Director of the Physics Invention Examination Department. From 1995 to 2004, he was Director of the Physics Invention Examination Department. Mr. Zhu Mingang was promoted as Senior Researcher in 2002. He has been Deputy Minister of the Material Engineering Examination Department since 2004.
Mr. Long is a patent attorney and assistant president of CCPIT Patent and Trademark Law Office.Long graduated from Tsinghua University with a Master Degree in Material Science and Engineering in 1993, and earned a Master of Law from Peking University in 2003. He joined CCPIT Patent and Trademark Law Office in 1994.Long was registered as a patent attorney in 1996 and got the attorney-at-law qualification in 1998. His practice focuses primarily on prosecution, invalidation, enforcement and licensing of patent. He has also counseled domestic and international clients on other IP related matters, such as trade secret, ownership dispute, and border enforcement. Long has considerable experience in handling patent invalidation and litigation cases for foreign companies. His technical specialty covers chemistry, chemical engineering, material science, pharmaceutics and agrochemicals etc.
Mr. Long is a council member of China Intellectual Property Society, a member of the All China Patent Agents Association, a member of Chinese group of AIPPI and LES China.
Ms. Tai，Assistant General Manager, Patent Attorney, Attorney-at-Law China Patent Agent (HK) Ltd.
Ms. Tai received, from Peking University, her B.S. in Applied Chemistry in 1990 and M.S. in Polymer Chemistry in 1993. She joined CPA in 1993, and qualified as a patent attorney in 1994. Ms. Tai was admitted to practice law in 1999. She took the LLM program at the University of London from 2002 to 2003. She received further training at a famous company in Germany in 1997, and at other German and British law firms in 2001. She participated in the Research Project on the Third Amendment to the Chinese Patent Law in 2005. As a patent attorney, Ms. Tai has represented many of our important Chinese and foreign clients in renowned invalidation cases and lawsuits. She represented Pfizer. Inc. as the chief attorney in both invalidation proceedings and court procedure involving the “Viagra” case. Besides, she is skillful in drafting patent application documents in such fields of technology as polymer, pharmaceutical chemistry, organic chemistry, organic synthesis, and experienced in preparing responses to office actions in the substantive examination proceedings, in handling cases of patent reexamination, invalidation and patent-related administrative litigation and infringement lawsuits, and in making infringement analysis. Ms. Tai is a member of the board of All-China Patent Agents Association, and a member of the Chinese Group of AIPPI.
Amy Feng is an attorney at law and patent attorney in China, and a partner at the law firm of Liu, Shen & Associates. Amy joined Liu Shen in 1996 and now has more than 13 year’s experience in the field of IP law. Ms. Feng specializes in all phases of patent prosecution, reexamination, patent invalidation, and patent litigation and counseling, including infringement as well as validity analysis in the chemical and biotech fields.
Ms. Feng is a member of the China Law Society, the Chinese Group of AIPPI, and the Chinese Patent Agents Association.
She received a bachelor’s of science degree in environmental engineering and a master’s of science degree in fine chemicals, both from Dalian University of Technology, China. During the period of 2002-2003, she studied civil and commercial law in the China University of Political Science and Law located in Beijing. In 2004, she earned an LL.M. degree in intellectual property law, with honors, from The John Marshall Law School in Chicago, where she also studied Biotech Patent Law related courses.
Ms. Feng has, for instance, lectured in dozens of European and US transnational chemical, pharmaceutical and biotech companies. She has also published many articles, such as an article entitled “Why Test Data Is Crucial”, published in the edition of China IP Focus China 2007, Managing Intellectual Property; an article entitled “The Importance of Parameter Selection for Polymorphs”, published in February, 2008, Managing Intellectual Property; and an article entitled “Take Local Practice into Account”, published in June, 2008, Managing Intellectual Property.
Ms. Heather Lin, Patent Attorney, Vice President of NTD Patent & Trademark Agency Ltd., received her Bachelor of Science degree in Biology from Fudan University in 1988 and Master of Science degree in Genetics from Institute of Microbiology, Chinese Academy of Sciences in 1991. She began to practice law in 1994 and in 1996 she became a qualified Patent Attorney. At NTD, she was sent to the United States and Japan respectively for different IP training programs. Her practice primarily involves patent drafting and prosecution with an emphasis on the areas of biotechnology and pharmaceuticals, and client counseling in the areas of IP strategic planning, infringement and validity of patents, etc. She is a frequent speaker in various IP forums (e.g., speaker, AIPLA 2005 Annual Meeting; speaker, China-ASEAN Intellectual Property Workshop 2008) and is often invited to give lectures on IP protection in universities and enterprises. She is a contributor of the China chapter of Biotechnology and Pharmaceutical Patents: Law and Practice (Aspen Publishers, Wolters Kluwer Law & Business, 2008, USA ) and also publishes several articles on biotech and pharmaceutical patent practice in China. Ms. Lin is a member of All-China Patent Agents Association (ACPAA), AIPPI and LES.
Dr. Zhu is president of China Science Patent and Trademark Agent Ltd., where he practices intellectual property laws and manages daily business operation. His current practice encompasses all aspects of intellectual property laws with emphasis on China IP strategy development, cross-border technology licensing and IP dispute resolutions.
Dr. Zhu previously worked as senior intellectual property counsel for Asia Pacific at General Electric Company in 2000-2005 where he was responsible for IP procurement and protection across the region with the main focus on China. He also served as chairman of the American Chamber of Commerce Shanghai’s IP subcommittee in 2002-2005 to advocate IP protection concerns by multinational companies and to share best practice.
Prior to joining GE, Dr. Zhu was with the U.S. law firm of Pennie & Edmonds for seven years, where he developed extensive experience and skills in IP law practice.
He was a frequent speaker at many international IP conferences. He has been recognized as a “Leading Lawyer” by Asialaw and “Leading Patent Specialist” by Chambers & Partner in 2008.
Confirmed Speakers from Oversea
Dr. Armstrong is a partner of Birch, Stewart, Kolasch & Birch, LLP. BSKB is one of the leading law firms in US patent prosecution. Dr. Armstrong’s practice includes the preparation and prosecution of patent applications dealing with diverse technologies, including pharmaceutical chemistry, immunology, biotechnology, organic chemistry, diagnostic assays and drug screening systems. Her practice also includes the preparation of due diligence and FTO opinions regarding issues of patentability, validity, infringement, and exemptions from infringement. Dr. Armstrong also has experience with FDA matters, including Patent Term Extension and Orange Book Listings and ANDAs/Paragraph IV certifications. Dr. Armstrong lectures around the world on patent matters. She is also a past member of the Advisory Committee for the Joint Commission of Science and Technology for the Virginia General Assembly.
Robert L. Baechtold is one of the founding partners of Fitzpatrick, Cella, Harper & Scinto. He was the Past President for Federal Circuit Bar Association and the Past Board Member for American Intellectual Property Law Association. He was selected as a top intellectual property law practitioner in every edition since 1995 of Best Lawyers in America. Over the past 40 years, Mr. Baechtold has prepared, tried and argued intellectual property cases primarily in the fields of pharmaceuticals, biotechnology, chemistry and polymeric materials. He has argued numerous appeals before the Court of Appeals for the Federal Circuit and has served as President of that Court's Bar Association.
Professor Margo Bagley is Professor of Law at The University of Virginia School of Law, where she teaches a variety of intellectual property courses including patent law and international patent law and policy. Her scholarship has focused on a number of aspects of patent law, including the role of morality in biotech patenting, access to essential medicines, and business method patents. Professor Bagley also has taught international patent law and policy in Germany, China and in Singapore. Professor Bagley worked as an associate with Smith, Gambrell & Russell and Finnegan, Henderson, Farabow, Garrett & Dunner before becoming a law professor at Emory University in 1999; she joined the University of Virginia faculty in 2006. Prior to pursuing a career in law, Professor Bagley worked in products research and development at the Procter & Gamble Company and as a senior research analyst for the Coca-Cola Company. Professor Bagley holds a B.S. in Chemical Engineering from the University of Wisconsin and a J.D.
Robert DeBerardine is the Global Head of Patents for sanofi-aventis and is based in Paris. Mr. DeBerardine is responsible for all aspects of sanofi-aventis’ patent portfolio and patenting strategies. Mr. DeBerardine has an extensive background in all facets of intellectual property law having served as Chief Patent Counsel for Abbott Laboratories, Assistant Chief Patent Counsel for Johnson & Johnson and as a trial attorney litigating patent cases when he was a partner at the law firms of Brobeck, Phleger and Harrison and earlier with the law firm of Jones, Day, Reavis and Pogue. Mr. DeBerardine has a Bachelors Degree in Chemical Engineering from Lafayette College and a Juris Doctor Degree from Cornell Law School.
Mr. Frank S. DiGiglio is the managing partner of Scully Scott Murphy & Presser, P.C., and also leads the firm's Biotech practice group. Mr. DiGiglio is experienced in patent and trademark litigation; extensive interference practice; Federal Circuit appeal practice; with technical emphasis in biotechnology, biochemistry and pharmaceutical sciences. Mr. DiGiglio received his B.S. in Biology from Boston College in 1975 and his J.D. from St. John's University School of Law in 1982. He was admitted to the New York State Bar in 1983, the U. S. District Court, Southern and Eastern Districts of New York, New York State Court of Appeals for the Second Circuit, and U.S. Court of Appeals for the Federal Circuit. Mr. DiGiglio is registered to practice before the U.S. Patent and Trademark Office, and is a member of the New York State Biotechnology Association, NYIPA and AIPLA. Mr. DiGiglio is an Adjunct Professor at Benjamin N. Cardozo School of Law (Yeshiva University) in Pharmaceutical and Biotechnology Patent Law.
Mr. Dunner served as chairman of the Advisory Committee to the U.S. Court of Appeals for the Federal Circuit for the first ten years of the Court’s existence and participated in the drafting of the Court’s rules (1982-92). He continuously served as chair or co-chair of the Planning Committee for the judicial conferences of the Court of Appeals and CCPA (1974-1992). Currently, Mr. Dunner is involved predominantly in intellectual property litigation and has earned the reputation of being one of the finest litigators in the country. He has litigated numerous cases in the federal district courts and is best known for appellate practice before the U.S. Court of Appeals for the Federal Circuit and its predecessor court, the U.S. Court of Customs and Patent Appeals. He has had significant success overturning jury and other verdicts handed down by lower district courts. The New York Times reported that he has argued more Federal Circuit cases than any other litigator in the U.S. Mr. Dunner was named International Lawyer of the Year for Patents by Who’s Who Legal: The International Who’s Who of Business Lawyers. In May 2008, he was listed in Legal Times’ “Greatest Washington Lawyers in the Past 30 Years.”
Mr. Hasford is an attorney in the Chemical Practice Group of the Washington, DC Office of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Mr. Hasford's practice focuses on complex patent litigation on behalf of pioneer pharmaceutical companies, including litigation arising from Abbreviated New Drug Applications under the Hatch-Waxman Act. Mr. Hasford additionally has litigated health care business method patents. Mr. Hasford has served as Chair and Program Chair of the Division of Chemistry and the Law of the American Chemical Society, as well as liaison to the Committee on Patents and Related Matters. Mr. Hasford also serves as Deputy General Secretary of the Second Beijing International Pharmaceutical and Chemical Intellectual Property Forum.
Tom Hockaday is the Managing Director of Isis Innovation Ltd, the technology transfer company of the University of Oxford. Tom joined Isis in March 2000, following seven years in technology transfer at Bristol University, where he was Managing Director of Bristol Innovations Ltd, and four years at University College London. Tom was Chairman of UNICO in 2003, the UK’s university technology transfer association.
Isis provides Oxford University researchers with commercial advice on patenting, licensing, and spin-out company formation. Isis manages Oxford University Consulting, providing access to the expertise of Oxford University’s academic expertise. Isis has concluded over 400 licence agreements, 250 consulting agreements, and assisted in the formation of 62 spin-out companies since 1997. Isis manages the University proof of concept and seed fund; works with the local NHS Hospital Trust to support their technology transfer activities; and in 2004 set up a division (Isis Enterprise) to provide consulting expertise on technology transfer to universities, research institutes and governments outside Oxford.
Mr. Irving is a partner of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, one of the world’s largest IP law firms. He is the Former Chair of the AIPLA's Chemical Practice Committee and a former member of AIPLA's Board of Directors, Co-chair of the Institute of Intellectual Property and Social Justice at the Howard University School of Law and Member of Board of Editors of BNA International's IP & Technology Program. Former adjunct professor of patent law at the American University School of Law. Principal lecturer in Patent Resource Group's Chemical Patent Practice, Due Diligence, and Orange Book courses. He has been selected by his peers for inclusion in The Best Lawyers in America since 2006. Mr. Irving has more than 33 years of experience in the field of intellectual property law. His practice encompasses all phases of due diligence, patent prosecution, reissue, and reexamination, patent interferences, and counseling, including pre-litigation, Orange Book listings of patents covering FDA-approved drugs, and infringement and validity analysis in the chemical fields, particularly pharmaceuticals and more particularly solid state substances. Mr. Irving has lectured before the chemical examiners at SIPO.
Dr. Frank Jiang, Vice President and Head of R&D China for Sanofi-Aventis (S-A),
is responsible for the global discovery research and clinical programs in China for
Wolfgang is Chairman of Bird & Bird’s offices in Germany and Joint Head of the
firm’s International Intellectual Property Group. He has established a leading
international reputation for IP litigation including patents, trade marks and
competition and antitrust matters. He is highly renowned for work in all areas
of IP, both nationally and internationally. Wolfgang has been involved in many
high-profile and technical patent cases, including those for the electronic,
life sciences and pharmaceutical sectors.
Hans Sauer is Associate General Counsel for Intellectual Property for the Biotechnology Industry Organization, a major trade association representing more than more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. Before joining BIO in 2006, Dr. Sauer served as chief patent counsel for MGI Pharma, Inc. and, before that, assistant general counsel for Guilford Pharmaceuticals, Inc, where he was responsible for patent prosecution, clinical research health information privacy, and sales and marketing legal compliance. Dr. Sauer began his industry career in 1995 as a postdoctoral fellow in the Dept. of Neuroscience of Genentech, Inc. He is a registered patent attorney and adjunct professor of law at Georgetown University Law Center. He holds a Master’s degree in biology from the University of Ulm in his native Germany, a Ph.D. in neuroscience from the University of Lund, Sweden, and a law degree from Georgetown University Law Center in Washington, D.C.
Mr. Watt is Vice President, Law and Intellectual Property Officer of Amgen Inc. and leads a group of 45 patent attorneys responsible for patent strategy, filing and prosecution of patent applications in the U.S. and foreign countries, patent litigation, and patent licensing. Mr. Watt has actively represented Amgen in patent litigation in the U.S. and various countries around the world. He joined Amgen in 1992. Prior to that time, he was associated with the patent law firm of Richards, Medlock & Andrews (now Sidley & Austin) in Dallas, Texas. Mr. Watt is a graduate of Brigham Young University (B.S.Ch.E. 1983) and the University of Washington School of Law (JD 1986).
Lawrence T. Welch is Assistant General Patent Counsel and Director, Global Patent Procurement Policies and Practices for Eli Lilly and Company, Indianapolis, Indiana. He has been with Lilly since 1998. In his current role, he manages the process for the acquisition of Lilly’s global patent portfolio, including the decisions related thereto. In addition, he chairs the Patent Enforcement Hub, an interdisciplinary group of patent attorneys, general attorneys, government affairs and regulatory personnel whose charter is to maximize global exclusivity for Lilly products. In connection with this role, he manages and coordinates global patent litigation for Lilly. Over the last six years, he has been involved with a number of contested patent matters in Asia, particularly in China. Prior to joining Lilly, he was with Pharmacia & Upjohn (P&U), and its predecessor, The Upjohn Company, for 19 years. His last position at P&U was Managing Patent Counsel and Director, Worldwide Patents. Larry has worked in all phases of patent practice, particularly pharmaceutical patent practice, both in the US and internationally. He has been active in professional and trade groups, including American Intellectual Property Law Association (AIPLA), ABA, Pharmaceutical Research and Manufacturers Association (PhRMA), and Pacific Intellectual Property Association (PIPA), and has held various leadership roles, including President of the American Group of PIPA.
China International Intellectual Property Forum Committee Copyright © 2006-2013
All rights reserved.
Web designing by geniestudio.com